Scholarlink

<p>Although prior research has investigated the link between fibrinogen and mortality risk, there is a notable lack of long-term cohort studies. This study seeks to examine the relationship between plasma fibrinogen levels and all-cause mortality. Fibrinogen levels were divided into low and high groups based on the median and further categorized into quartiles. Kaplan-Meier analysis was employed for survival analysis, and hazard ratios (HRs) were calculated using the Cox proportional hazards model. Our study included 5,690 participants, divided into a lower fibrinogen group (fibrinogen ≤ 370&#xa0;mg/dL, <i>N</i> = 2,851) and a higher fibrinogen group (fibrinogen &gt; 370&#xa0;mg/dL, <i>N</i> = 2,839). The survival probability of the lower fibrinogen group was higher than that of the higher group (70.98% vs. 47.98%, <i>P</i> &lt; 0.0001). All-cause mortality was higher in the higher fibrinogen group compared to the low fibrinogen group (HR 1.26, 95% CI 1.09–1.45, <i>P</i> = 0.002). Compared to Q1, mortality risk increased in Q2 (HR 1.26, 95% CI 1.00–1.59, <i>P</i> = 0.05), Q3 (HR 1.39, 95% CI 1.15–1.69, <i>P</i> &lt; 0.001), and Q4 (HR 1.51, 95% CI 1.23–1.87, <i>P</i> &lt; 0.001). Higher fibrinogen levels correlate with an elevated risk of all-cause mortality, suggesting fibrinogen is a potential biomarker for mortality risk.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Associations between fibrinogen levels and the risk of all-cause mortality: a long-term cohort study

  • 期刊论文

  • 发表日期：

    2025年4月23日

查看全文
  • Xinru Hu,
  • Junwen Wang,
  • Yuyang Ye,
  • Xuefeng Chen,
  • Simayi Abulikemu,
  • Jiang Yu,
  • Yifei Zhao,
  • Teng Hu,
  • Yong Peng

摘要

Although prior research has investigated the link between fibrinogen and mortality risk, there is a notable lack of long-term cohort studies. This study seeks to examine the relationship between plasma fibrinogen levels and all-cause mortality. Fibrinogen levels were divided into low and high groups based on the median and further categorized into quartiles. Kaplan-Meier analysis was employed for survival analysis, and hazard ratios (HRs) were calculated using the Cox proportional hazards model. Our study included 5,690 participants, divided into a lower fibrinogen group (fibrinogen ≤ 370 mg/dL, N = 2,851) and a higher fibrinogen group (fibrinogen > 370 mg/dL, N = 2,839). The survival probability of the lower fibrinogen group was higher than that of the higher group (70.98% vs. 47.98%, P < 0.0001). All-cause mortality was higher in the higher fibrinogen group compared to the low fibrinogen group (HR 1.26, 95% CI 1.09–1.45, P = 0.002). Compared to Q1, mortality risk increased in Q2 (HR 1.26, 95% CI 1.00–1.59, P = 0.05), Q3 (HR 1.39, 95% CI 1.15–1.69, P < 0.001), and Q4 (HR 1.51, 95% CI 1.23–1.87, P < 0.001). Higher fibrinogen levels correlate with an elevated risk of all-cause mortality, suggesting fibrinogen is a potential biomarker for mortality risk.